News | January 05, 2023
Yaral Pharma launches diclofenac epolamine topical system 1.3%
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
To create leading company developing medicines targeting metalloenzymes
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Subscribe To Our Newsletter & Stay Updated
